Tag: MS
Bristol Myers Squibb’s Zeposia launches into crowded MS market
When Bristol Myers Squibb nabbed Celgene's long-sought FDA nod for multiple sclerosis drug Zeposia, the COVID-19 pandemic was in full swing—not the ideal time...
Teva forecasts worse-than-expected ‘trough year’ as generics hammer MS drug Copaxone
Shares of Teva fell nearly 12% in pre-market trading to $16.80 after the company’s executives conceded during the fourth-quarter earnings report that 2019 would...
